Conversely, when considering the extensive use of SGLT2 inhibitors during hospitalization for acute ischemic events, decisions should be guided by the presence of heart failure signs, the type and extent of myocardial damage, the timing and approach of the revascularization strategy, the risk of cardiogenic shock, and the patient's underlying metabolic status. This evidence concerns the gene SLC5A2 and heart failure.